LV12522B - Bisulfate salt of hiv protease inhibitor - Google Patents
Bisulfate salt of hiv protease inhibitor Download PDFInfo
- Publication number
- LV12522B LV12522B LVP-00-78A LV000078A LV12522B LV 12522 B LV12522 B LV 12522B LV 000078 A LV000078 A LV 000078A LV 12522 B LV12522 B LV 12522B
- Authority
- LV
- Latvia
- Prior art keywords
- salt
- free base
- bisulfate salt
- bisulfate
- solubility
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7196898P | 1998-01-20 | 1998-01-20 | |
PCT/US1998/027382 WO1999036404A1 (en) | 1998-01-20 | 1998-12-22 | Bisulfate salt of hiv protease inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
LV12522A LV12522A (en) | 2000-08-20 |
LV12522B true LV12522B (en) | 2000-10-20 |
Family
ID=22104737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-00-78A LV12522B (en) | 1998-01-20 | 2000-06-06 | Bisulfate salt of hiv protease inhibitor |
Country Status (39)
Country | Link |
---|---|
US (1) | US6087383A (de) |
EP (1) | EP1056722B1 (de) |
JP (2) | JP4860037B2 (de) |
KR (1) | KR100559283B1 (de) |
CN (1) | CN1116282C (de) |
AR (1) | AR014417A1 (de) |
AT (1) | ATE219057T1 (de) |
AU (1) | AU735875B2 (de) |
BG (1) | BG64774B1 (de) |
BR (1) | BR9814736A (de) |
CA (1) | CA2317736C (de) |
CO (1) | CO4970820A1 (de) |
CZ (1) | CZ293507B6 (de) |
DE (1) | DE69806067T2 (de) |
DK (1) | DK1056722T3 (de) |
EE (1) | EE04434B1 (de) |
EG (1) | EG23936A (de) |
ES (1) | ES2178300T3 (de) |
GE (1) | GEP20033026B (de) |
HK (2) | HK1033667A1 (de) |
HU (1) | HU227196B1 (de) |
IL (2) | IL137384A0 (de) |
LT (1) | LT4780B (de) |
LV (1) | LV12522B (de) |
MY (1) | MY114838A (de) |
NO (1) | NO315605B1 (de) |
NZ (1) | NZ504417A (de) |
PE (1) | PE20000185A1 (de) |
PL (1) | PL190744B1 (de) |
PT (1) | PT1056722E (de) |
RO (1) | RO118869B1 (de) |
RU (1) | RU2186070C2 (de) |
SK (1) | SK283975B6 (de) |
TR (1) | TR200001876T2 (de) |
TW (1) | TW531531B (de) |
UA (1) | UA59432C2 (de) |
UY (1) | UY25345A1 (de) |
WO (1) | WO1999036404A1 (de) |
ZA (1) | ZA9956B (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2448084A1 (en) * | 2001-05-22 | 2002-11-28 | Elan Pharmaceuticals, Inc. | Aza hydroxylated ethyl amine compounds |
US7157561B2 (en) * | 2001-07-13 | 2007-01-02 | Roche Diagnostics Operations, Inc. | Methods of inhibiting transmission of a costimulatory signal of lymphocytes |
US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
EA015145B1 (ru) * | 2003-01-14 | 2011-06-30 | Джилид Сайэнс, Инк. | Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции |
TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
CN1980666B (zh) * | 2004-05-04 | 2011-03-30 | 布里斯托尔-迈尔斯斯奎布公司 | 制备阿扎那韦硫酸氢盐的方法和新的形式 |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
TWI354569B (en) * | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US7642049B2 (en) * | 2006-06-30 | 2010-01-05 | Bristol-Myers Squibb Company | Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms |
PT2069303E (pt) * | 2006-07-21 | 2016-06-08 | Gilead Sciences Inc | Inibidores de protease antiviral |
BG66056B1 (bg) * | 2006-10-05 | 2010-12-30 | Красимир ДЕЧЕВ | Метод и инсталация за производство на трисезонна добавка към дизелово гориво |
ES2395137T3 (es) * | 2007-06-12 | 2013-02-08 | Concert Pharmaceuticals, Inc. | Derivados de azapéptidos como inhibidores de la proteasa VIH |
JP2010530889A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
PL2170292T3 (pl) * | 2007-06-22 | 2014-06-30 | Bristol Myers Squibb Holdings Ireland | Tabletkowane kompozycje zawierające atazanawir |
JP2010530892A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
US20100178340A1 (en) * | 2007-06-22 | 2010-07-15 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
UA103881C2 (ru) * | 2007-06-29 | 2013-12-10 | Гилиад Сайенсиз, Инк. | Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека |
US20100331331A1 (en) * | 2007-06-29 | 2010-12-30 | Therapeutic Compositons And Use Thereof | Therapeutic compositions and the use thereof |
EP2288593A1 (de) * | 2008-05-08 | 2011-03-02 | Ranbaxy Laboratories Limited | Verfahren zur herstellung von 3,4-epoxy-2-amino-1-substituierten butanderivaten und zwischenprodukte dafür |
WO2010070611A1 (en) | 2008-12-18 | 2010-06-24 | Ranbaxy Laboratories Limited | Atazanavir formulations |
US8552036B2 (en) | 2009-01-12 | 2013-10-08 | Hetero Research Foundation | Polymorph of atazanavir sulfate |
CA2762582A1 (en) | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
EP2272830A1 (de) | 2009-06-18 | 2011-01-12 | Esteve Química, S.A. | Herstellungsverfahren für ein antivirales heterozyklisches Azahexan-Derivat |
WO2011027324A1 (en) | 2009-09-03 | 2011-03-10 | Ranbaxy Laboratories Limited | Polymorphic forms of atazanavir sulfate |
AU2010313571B2 (en) | 2009-10-26 | 2014-07-31 | Merck Sharp & Dohme Llc | Solid pharmaceutical compositions containing an integrase inhibitor |
WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
SG10201509476RA (en) | 2010-01-27 | 2015-12-30 | Viiv Healthcare Co | Antiviral therapy |
US20130005780A1 (en) | 2010-03-01 | 2013-01-03 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
CN102917695A (zh) | 2010-04-09 | 2013-02-06 | 百时美施贵宝公司 | 具有改进的pH效应的阿扎那韦硫酸盐制剂 |
EA201390464A1 (ru) | 2010-09-28 | 2013-08-30 | Рациофарм Гмбх | Способ сухой обработки атазанавира |
WO2013014633A1 (en) | 2011-07-27 | 2013-01-31 | Ranbaxy Laboratories Limited | Process for preparation of atazanavir or its bisulfate salt |
US8461347B2 (en) | 2011-08-05 | 2013-06-11 | Scinopharm Taiwan, Ltd. | Process for preparing form A of atazanavir sulfate |
WO2013059928A1 (en) | 2011-10-26 | 2013-05-02 | Merck Canada Inc. | Hiv protease inhibitors |
EP2888230A4 (de) | 2012-08-24 | 2017-07-19 | Laurus Labs Private Limited | Verbessertes verfahren zur herstellung von atazanavirbisulfat |
WO2014036690A1 (zh) * | 2012-09-04 | 2014-03-13 | 上海迪赛诺化学制药有限公司 | 制备阿扎那韦硫酸氢盐a型结晶的方法 |
US9890121B2 (en) | 2013-02-12 | 2018-02-13 | Cipla Limited | Process for preparing atazanavir sulphate |
CN104250223B (zh) * | 2013-06-28 | 2017-04-12 | 上海威智医药科技有限公司 | 阿扎那韦氢溴酸盐及其制备和应用 |
CN104250225A (zh) * | 2013-06-28 | 2014-12-31 | 上海威智医药科技有限公司 | 阿扎那韦磷酸盐及其制备和应用 |
CN104250224A (zh) * | 2013-06-28 | 2014-12-31 | 上海威智医药科技有限公司 | 阿扎那韦富马酸盐及其制备和应用 |
CN105859611A (zh) * | 2016-04-18 | 2016-08-17 | 上海现代制药海门有限公司 | 一种阿扎那韦硫酸氢盐a型结晶的制备方法 |
CN109251165B (zh) * | 2018-10-02 | 2022-09-23 | 国药集团川抗制药有限公司 | 阿扎那韦达二4-氨基苯磺酸盐及其制备方法 |
CN111349042B (zh) * | 2018-12-20 | 2023-07-14 | 陕西理工大学 | 一种阿扎那韦单晶及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
TW409125B (en) * | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
-
1998
- 1998-12-21 US US09/217,538 patent/US6087383A/en not_active Expired - Lifetime
- 1998-12-22 UA UA2000084931A patent/UA59432C2/uk unknown
- 1998-12-22 TR TR2000/01876T patent/TR200001876T2/xx unknown
- 1998-12-22 PL PL342019A patent/PL190744B1/pl unknown
- 1998-12-22 DE DE69806067T patent/DE69806067T2/de not_active Expired - Lifetime
- 1998-12-22 ES ES98964878T patent/ES2178300T3/es not_active Expired - Lifetime
- 1998-12-22 AU AU20101/99A patent/AU735875B2/en not_active Expired
- 1998-12-22 WO PCT/US1998/027382 patent/WO1999036404A1/en active IP Right Grant
- 1998-12-22 DK DK98964878T patent/DK1056722T3/da active
- 1998-12-22 JP JP2000540121A patent/JP4860037B2/ja not_active Expired - Lifetime
- 1998-12-22 IL IL13738498A patent/IL137384A0/xx active IP Right Grant
- 1998-12-22 EE EEP200000798A patent/EE04434B1/xx unknown
- 1998-12-22 CZ CZ20002564A patent/CZ293507B6/cs not_active IP Right Cessation
- 1998-12-22 EP EP98964878A patent/EP1056722B1/de not_active Expired - Lifetime
- 1998-12-22 SK SK1062-2000A patent/SK283975B6/sk not_active IP Right Cessation
- 1998-12-22 CA CA002317736A patent/CA2317736C/en not_active Expired - Lifetime
- 1998-12-22 RU RU2000119792/04A patent/RU2186070C2/ru active
- 1998-12-22 BR BR9814736-6A patent/BR9814736A/pt not_active Application Discontinuation
- 1998-12-22 GE GEAP19985466A patent/GEP20033026B/en unknown
- 1998-12-22 NZ NZ504417A patent/NZ504417A/en not_active IP Right Cessation
- 1998-12-22 RO ROA200000717A patent/RO118869B1/ro unknown
- 1998-12-22 KR KR1020007007885A patent/KR100559283B1/ko not_active IP Right Cessation
- 1998-12-22 CN CN98812741A patent/CN1116282C/zh not_active Expired - Lifetime
- 1998-12-22 PT PT98964878T patent/PT1056722E/pt unknown
- 1998-12-22 AT AT98964878T patent/ATE219057T1/de active
- 1998-12-22 HU HU0101389A patent/HU227196B1/hu unknown
-
1999
- 1999-01-05 MY MYPI99000020A patent/MY114838A/en unknown
- 1999-01-05 ZA ZA9900056A patent/ZA9956B/xx unknown
- 1999-01-12 UY UY25345A patent/UY25345A1/es not_active Application Discontinuation
- 1999-01-15 TW TW088100623A patent/TW531531B/zh not_active IP Right Cessation
- 1999-01-17 EG EG5699A patent/EG23936A/xx active
- 1999-01-18 AR ARP990100179A patent/AR014417A1/es active IP Right Grant
- 1999-01-19 CO CO99002578A patent/CO4970820A1/es unknown
- 1999-01-20 PE PE1999000047A patent/PE20000185A1/es not_active IP Right Cessation
-
2000
- 2000-06-06 LV LVP-00-78A patent/LV12522B/en unknown
- 2000-07-14 LT LT2000067A patent/LT4780B/lt not_active IP Right Cessation
- 2000-07-17 BG BG104618A patent/BG64774B1/bg unknown
- 2000-07-19 NO NO20003692A patent/NO315605B1/no not_active IP Right Cessation
- 2000-07-19 IL IL137384A patent/IL137384A/en not_active IP Right Cessation
-
2001
- 2001-04-26 HK HK01103011A patent/HK1033667A1/xx not_active IP Right Cessation
- 2001-06-15 HK HK01104126A patent/HK1033458A1/xx not_active IP Right Cessation
-
2008
- 2008-12-17 JP JP2008321240A patent/JP2009102357A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6087383A (en) | Bisulfate salt of HIV protease inhibitor | |
CA2433288C (en) | Process for making amlodipine maleate | |
EP3168211A1 (de) | Pharmazeutische co-kristalle von niclosamid | |
KR20150020683A (ko) | 다사티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정 | |
CS265250B2 (en) | Process for preparing anhydrous crystalline natrium salt of 5-chlor-3-/2-thenoyl/-2-oxindol-1-carboxamide | |
EP1461036A2 (de) | Bis-hydrochlorid-monohydratsalz des rsv-fusionshemmers | |
MXPA00006747A (en) | Bisulfate salt of hiv protease inhibitor | |
CZ20014270A3 (cs) | Polymorfy krystalického citrátu (2-benzhydryl-1-azabicyklo[2.2.2]oct-3-yl)-(5-iso-propyl-2-methoxybenzyl)-aminu jako antagonisté receptoru NK-1 | |
US2991288A (en) | Camphidine derivatives | |
AU2001100432A4 (en) | Process for making amlodipine maleate | |
NL1018754C1 (nl) | Werkwijze voor het maken van amlodipinemaleaat. | |
EA008141B1 (ru) | Способ получения малеата амлодипина | |
SI21068A2 (sl) | Amlodipin maleat ali njegova kislinska adicijska sol |